Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 18/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 18/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30919790 | 0.96 | DDB1 (0.53) | DDB1CRBNPSEN1PSEN2APH1B | |
| SCHEMBL27265870 | 0.96 | DDB1 (0.53) | DDB1CRBNPSEN1PSEN2APH1B | |
| SCHEMBL31601585 | 0.89 | CRBN (0.52) | DDB1CRBN | |
| SCHEMBL30938883 | 0.88 | DDB1 (0.59) | DDB1CRBN | |
| SCHEMBL31553731 | 0.86 | DDB1 (0.54) | DDB1CRBN | |
| SCHEMBL27178269 | 0.85 | CRBN (0.47) | DDB1CRBN | |
| SCHEMBL23842106 | 0.85 | DDB1 (0.64) | DDB1CRBN | |
| SCHEMBL31218844 | 0.84 | DDB1 (0.58) | DDB1CRBN | |
| SCHEMBL29971694 | 0.84 | DDB1 (0.44) | DDB1CRBNPSEN1PSEN2APH1B | |
| SCHEMBL19586978 | 0.84 | DDB1 (0.44) | DDB1CRBNPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630415-A1 | TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2025-10-15 | — | — | EP | disclosed |
| EP-4630414-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121259-A1 | TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121256-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-06-13 | — | — | WO | disclosed |